Product Name: Retatrutide Lyophilized Powder

CAS No.: 2381089-83-2

Molecular Formula: C221H342N46O68

Molecular Weight: 4730.91

Purity: ≥99.0%

Dosages: 5mg/Vial, 10mg/Vial, 15mg/Vial, 20mg/Vial, 30mg/Vial or customized.

Brief Introduction:

Retatrutide is an active compound released by Eli Lilly in June 2023. It is a triple (GLP-1/GIP/Gcg) agonist based on the GLP/GI dual receptor agonist Tirzepatide through a hybrid glucagon (GlucagonGcg) related structure, and is a drug for the treatment of obesity and type 2 diabetes. This active compound can activate receptor agonists in our body, which helps control blood sugar and weight loss management.

Sequence:

H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Mechanism of Action:

Retatrutide achieves comprehensive metabolic regulation through triple receptor activation:

※ GLP-1R: Slows gastric emptying, enhances satiety, and reduces appetite.

※ GIPR: Regulates hunger signals in the central nervous system, further suppresses appetite and improves energy metabolism.

※ GCGR: Promotes glucagon secretion, accelerates fat and glycogenolysis, and increases basal metabolic rate.

Indications and Efficacy:

★ Obesity Treatment:
In the Phase II clinical trial, patients in the highest dose group (12 mg) lost an average of 24.2% weight after 48 weeks, and some patients lost more than 30%.

★ Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD):
Retatrutide can reduce liver fat content by 86%, and more than 85% of patients achieve regression of liver steatosis.

★ Type 2 Diabetes:
Significantly reduce glycated hemoglobin (HbA1c) and improve blood sugar control.

★ Potential Cardiovascular Benefits:
Animal studies have shown that it may indirectly protect cardiovascular health by improving blood pressure and heart function, but further clinical verification is needed.

Market Prospects and Challenges:

◎ Differentiation Advantages:

Compared with existing GLP-1 single-target (such as Semaglutide) or dual-target drugs (such as Tirzepatide), the triple mechanism of retasopeptide has greater potential in weight loss and metabolic improvement.

◎ Cost and Accessibility:
Currently, the production cost of peptide drugs is relatively high, but the long-acting properties of retasopeptide may reduce the frequency of medication and improve patient compliance.

Laboratory & Equipment:

Product Display:

Third-party Test Report:

Packaging of our Retatrutide Lyophilized Powder:

10 Vials per Box (5mg/vial*10vials, 10mg/vial*10vials, 15mg/vial*10vials, 20mg/vial*10vials or 30mg/vial*10vials).

Payment Methods:

Storage Conditions:

Preserved in air tight containers, protected from light.
(Recommended temperature: -25℃ ~ -15℃)

Shelf Life:

24 months from the date of manufacturing when stored under the above conditions.